Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: Lexaria bioscience corp | History Defined

Lexaria's DehydraTECH CBD Hypertension Study Dosing Complete With No Serious Adverse Events

Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) revealed that dosing with Lexaria's DehydraTECH-processed CBD has been completed in its multi-week human clinical hypertension study HYPER-H21-4

Benzinga · Jul 27, 2022

Why Shares Of Lexaria Biosciences Are Trading Higher

Why Shares Of Lexaria Biosciences Are Trading Higher

Lexaria Bioscience Corp. (NASDAQ: LEXX) shares are trading higher after the company announced manufacturing and license agreements with BevNology.

Benzinga · Jun 21, 2022

Lexaria Posied To Receive US Patent For DehydraTECH To Deliver Antiviral Drugs

Lexaria Posied To Receive US Patent For DehydraTECH To Deliver Antiviral Drugs

Lexaria Bioscience Corp (NASDAQ:LEXX) is receiving its first-ever patent for DehydraTECH technology in the enhanced delivery of antiviral drugs. Lexaria has received notification from the United States Patent and Trademark Office that patent 11,311,559 for Compositions and Methods For Enhanced Delivery Of Antiviral Agents will be issued to the Company on April 26. "This…

Benzinga · Apr 21, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why Lexaria Shares Are Rising Today

Lexaria Bioscience Corp (NASDAQ:LEXX) said that all data analyses from its simulated pulmonary hypertension clinical study HYPER-H21-3 are complete, assessing a single 300mg dose of DehydraTECH-processed cannabidiol (DehydraTECH-CBD). The study findings indicated a tendency (p=0.1) during 15 minutes of simulated low levels of oxygen (hypoxia) for reduced pulmonary artery systolic pressure (PASP)…

Benzinga · Apr 14, 2022

1

Coverage From

Benzinga

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

422,981 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play